표준용량 양성자펌프억제제에 반응을 보이지 않는 비미란성 역류질환 환자에서 Esomeprazole 40 mg 단일 요법의 유효성: 다기관 공개 연구 = The Effect of Esomeprazole 40 mg Single Therapy in Patients with Non-Erosive Reflux Disease Who Are Resistant to Standard-Dose Proton Pump Inhibitor Therapy: An Open-Label Multicenter Study

다국어 초록 (Multilingual Abstract)

Background/Aims: Despite the efficacy of proton pump inhibitor (PPI) treatment, a considerable number of patients with non-erosive reflux disease (NERD) are resistant to treatment with a PPI at the standard dose. In these patients, doubling the dose of PPI is one of the potential therapeutic strategies. However, only few studies support this therapeutic strategy. The aim of this study was to assess the efficacy and safety of 40 mg esomeprazole once daily in patients with persistent symptoms of NERD despite standard daily PPI therapy. Materials and Methods: A total of 92 patients with NERD who had persistent symptoms of NERD despite standard dose (half dose) of PPI for more than 4 weeks, were enrolled in this multicenter (eight centers) open-label study. Efficacy and safety of a daily dose of 40 mg esomeprazole were evaluated after 4 weeks in all the patients. Results: The sum score of two symptoms (heartburn and regurgitation) decreased significantly from 72.51 to 32.55 after 4 weeks of treatment (P＜0.001). The percentage of patients with ≥50% improvement in symptom score (heartburn +acid regurgitation), during the study period was 66.7%. Patients with severe symptoms at baseline had significantly higher symptom improvement rate in comparison to patients who had milder symptoms. Adverse effects related to the treatment were reported by 3 (3.3%) patients. Conclusions: Esomeprazole 40 mg once daily is an effective and safe strategy to treat NERD patients with persistent symptoms despite standard daily PPI therapy.

참고문헌 (Reference)

1 Fass R, "Treatment of patients with persistent heartburn symptoms: a double-blind, randomized trial" 4 : 50-56, 2006

2 Jones R, "The effectiveness of esomeprazole 40 mg in patients with persistent symptoms of gastro-oesophageal reflux disease following treatment with a full dose proton pump inhibitor" 62 : 1844-1850, 2008

3 Cloud ML, "Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group" 43 : 993-1000, 1998

4 Miner P Jr, "Rabeprazole in nonerosive gastroesophageal reflux disease: a randomized placebo-controlled trial" 97 : 1332-1339, 2002

5 Robinson M, "Onset of symptom relief with rabeprazole:a community-based, open-label assessment of patients with erosive oesophagitis" 16 : 445-454, 2002

6 Kim JJ, "Multicenter study to evaluate the effect of esomeprozole in gastro-esophageal reflux disease" 9 : 92-101, 2003

7 Khan M, "Medical treatments in the short term management of reflux oesophagitis" (2) : CD003244-, 2007

8 Furuta T, "Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan" 46 : 1273-1283, 2011

9 Katz PO, "Guidelines for the diagnosis and management of gastroesophageal reflux disease" 108 : 308-328, 2013

10 Miner P Jr, "Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study" 98 : 2616-2620, 2003

11 Galmiche JP, "Functional esophageal disorders" 130 : 1459-1465, 2006

12 Matsuhashi N, "Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study" 50 : 1173-1183, 2015

13 Kahrilas PJ, "Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators" 14 : 1249-1258, 2000

14 Röhss K, "Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20mg in patients with gastro-oesophageal reflux symptoms" 60 : 531-539, 2004

15 Castell DO, "Esomeprazole (40 mg)compared with lansoprazole (30 mg) in the treatment of erosive esophagitis" 97 : 575-583, 2002

16 Fass R, "Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics" 41 : 131-137, 2007

17 Miwa H, "Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from Japan" 26 : 69-77, 2007

18 Richter JE, "Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial" 96 : 656-665, 2001

19 Modlin IM, "Diagnosis and management of non-erosive reflux disease--the Vevey NERD Consensus Group" 80 : 74-88, 2009

20 Katz PO, "Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms" 25 : 197-205, 2007